Compared with chemotherapy as a former treatment of choice, TKI-based therapy revolutionized the overall survival and the quality of life of NSCLC patients, especially if they are carriers of the EGFR driver mutations [20–23]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.